Steincares and Molteni Farmaceutici Expand Access to Pain Treatment in Latin America

• The agreement includes the exclusive marketing and distribution of Oramorph® a novel morphine oral solution with presence in over 35 countries worldwide in Ecuador, Brazil, and Mexico.
• This alliance reinforces SteinCares’ role as a bridge between Latin America’s unmet healthcare needs and global advancements in specialty care.

San Jose, Costa Rica, January 2025-. SteinCares, a leading specialty healthcare company in Latin America, has announced a commercialization agreement with Molteni Farmaceutici, an Italian company specializing in pain management, to expand access to Oramorph®, a Molteni Farmaceutici proprierty pharma product novel morphine oral solution across the region. The companies will officially launch their partnership in Ecuador at the end of 2025, with launches planned for Brazil and Mexico in 2027. The agreement aligns with SteinCares’ regional inorganic expansion strategy, following the acquisition of C&D Pharma in Chile.

Morphine offers key advantages for managing severe pain, including proven efficacy, flexible administration options for both acute and chronic pain control, rapid onset of action, cost-effectiveness, all essential for addressing a wide range of patient needs.
“Molteni Farmaceutici’s commitment to pain management perfectly aligns with our purpose of creating healthcare opportunities that positively impact the lives of patients and their families”, said Mitchell Waserstein, CEO of SteinCares. “This partnership allows us to address Latin America’s significant unmet need for effective pain therapies and further advance our shared vision of a healthier future for the region.”

“By combining our expertise in pain management with SteinCares’ established presence and deep understanding of the Latin American market, we are creating a powerful synergy that will greatly benefit patients. We look forward to collaborating further to address the ongoing challenges of pain management in the region”, affirmed Mr. Gianluca Corbinelli, CEO of Molteni Farmaceutici.
Untreated or inadequately treated pain is a significant challenge for many patients with chronic diseases in Latin America, particularly in patients with advanced cancer. Limited access to effective analgesics severely impacts patients and their caregiver’s quality of life, affecting their physical, psychological, and social well-being. Through this new agreement, SteinCares and Molteni Farmaceutici are making a lasting impact on specialty healthcare in Latin America.

About SteinCares
SteinCares is a leader in the commercialization and distribution of specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars and complex generics. With more than 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region.
For more information, visit www.steincares.com.

About Molteni Farmaceutici
Molteni Farmaceutici is an Italian pharmaceutical company, a specialty pharma leader in therapeutics solutions for pain management and drug addiction. Founded in 1892 and headquartered in Florence, Italy.

With its own Manufacturing, R&D, Regulatory, Supply Chain and Commercial capabilities it is able to serve a broad distribution reach in Europe and across the globe.